Evidence map›Paper›PMID 14715048›Full record

ReviewClinical pharmacokinetics2004

Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Trino Baptista, N M K Ng Ying Kin, Serge Beaulieu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical pharmacokinetics, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Trino BaptistaDepartment of Physiology, Los Andes University Medical School, Mérida, Venezuela. trinbap@yahoo.com
N M K Ng Ying Kin
Serge Beaulieu
Douglas Mental Health University Institute · CAMcGill University · CAUniversity of the Andes · VE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The risk of excessive bodyweight gain, glucose dysregulation and hyperlipidaemia is differentially increased by conventional and atypical antipsychotic drugs. Switching or combining agents may be sufficient in some cases, but in many instances additional drug treatment will be required. This includes oral antidiabetics, insulin and agents to treat hyperlipidaemia, hypertension and platelet dysfunction, among others. Numerous pharmacokinetic and pharmacodynamic interactions with the antipsychotics are possible, although few have been tested in formal studies. After reviewing the literature, the authors provide preliminary guidelines to assist clinicians in drug selection for this complex and fragile clinical population.

Indexed as

Antipsychotic AgentsDrug InteractionsHumansHypoglycemic AgentsHypolipidemic AgentsMetabolic SyndromeAntipsychotic AgentsHypoglycemic AgentsHypolipidemic Agents

Identifiers

PMID14715048
OpenAlexW2025835403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.